biostudies-literatureFregonese FWorld Health OrganizationIntramural CDC HHSCIHR265-275https://www.ebi.ac.uk/biostudies/studies/S-EPMC9017096biostudies-literatureUnknown6(4)<h4>Background</h4>Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.<h4>Methods</h4>Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. StudiThe Lancet. Respiratory medicineComparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.PMC9017096001CC999999Jacobson KRTabarsi PCegielski PYoshiyama TBastos MMunang MTrajman AGoldberg SEscalante PNguyen VNErkens CLee JHBaghaei PSkrahina AReves RCattamanchi ALi PZFregonese FAyakaka IMenzies DGriffith DMaciel ELMerle CSCPonnuraja CBenedetti AArakaki-Sanchez DSeung KSchaaf HSJones-Lopez ECChien JYKoh WJGarcia-Prats AJAhuja SDNarendran GBang DGalliez RMOhkado AGlynn JRBonnet MGillespie SHJohnston JCSoolingen DVRomanowski KFalzon DKhan ATrieu LDedicoat MWang JYPark JSCox HBanurekha VVNunn AAkkerman OWKritski AViiklepp PGegia MLan ZYPhillips PPJfalseComparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.<h4>Background</h4>Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.<h4>Methods</h4>Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studi2018-01-01T00:00:00Z2018 Apr2026-06-03T10:17:48.74Z2025-02-18T23:35:47.492ZS-EPMC90170962959550910.1016/S2213-2600(18)30078-X10.1016/s2213-2600(18)30078-x